P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging

Cytometry Part A

Volumn 79 A, Issue 11, 2011, Pages 912-919

  Vilas Boas, Vânia ^a   Silva, Renata ^a   Gaio, A Rita ^a   Martins, Ana Margarida ^a   Lima, Sofia Costa ^b   Cordeiro da Silva, Anabela ^a,b   de Lourdes Bastos, Maria ^a   Remião, Fernando ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Aging; Flow cytometry; P glycoprotein; Rho 123 efflux; UIC2 shift assay

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORESCENT DYE; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; RHODAMINE 123; VINBLASTINE;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; CAUCASIAN; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; HUMAN; LYMPHOCYTE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGED; AGING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLOW CYTOMETRY; FLUORESCENT DYES; GENE EXPRESSION; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; REGRESSION ANALYSIS; RHODAMINE 123; VINBLASTINE;

EID: 80054897494     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.21135     Document Type: Article

References (33)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
3. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 2007; 113: 429-441.
4. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359.
5. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
6. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-1310.
7. Benson ABIII, Trump DL, Koeller JM, Egorin MI, Olman EA, Witte RS, Davis TE, Tormey DC. Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep 1985; 69: 795-799.
8. Gruber A, Bjorkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Lofvenberg E, Nesthus I, Simonsson B, et al. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res 2003; 27: 323-328.
9. Dinis-Oliveira RJ, Remiao F, Duarte JA, Ferreira R, Sanchez Navarro A, Bastos ML, Carvalho F. P-glycoprotein induction: An antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med 2006; 41: 1213-1224.
10. Silva R, Carmo H, Dinis-Oliveira R, Cordeiro-da-Silva A, Lima SC, Carvalho F, de Lourdes Bastos M, Remiao F. In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol 2010; 85: 315-326.
11. Miller RA. The aging immune system: Primer and prospectus. Science 1996; 273: 70-74.
12. Aggarwal S, Tsuruo T, Gupta S. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. J Clin Immunol 1997; 17: 448-454.
13. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004; 60: 97-102.
14. Machado CG, Calado RT, Garcia AB, Falcao RP. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. Braz J Med Biol Res 2003; 36: 1653-1657.
15. Storch CH, Klimm HD, Heinrich T, Haefeli WE, Weiss J. Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 135-143.
16. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 1996; 56: 3010-3020.
17. Mechetner EB, Schott B, Morse BS, Stein WD, Druley T, Davis KA, Tsuruo T, Roninson IB. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci USA 1997; 94: 12908-12913.
18. Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A 2003; 53: 67-78.
19. Klimecki WT, Taylor CW, Dalton WS. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J Clin Immunol 1995; 15: 152-158.
20. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458.
21. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735-2739.
22. Cianfriglia M, Dupuis ML, Molinari A, Verdoliva A, Costi R, Galluzzo CM, Andreotti M, Cara A, Di Santo R, Palmisano L. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 2007; 4: 17.
23. Taylor BJ, Olson DP, Ivy SP. Detection of P-glycoprotein in cell lines and leukemic blasts: Failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cells. Leuk Res 2001; 25: 1127-1135.
24. Shirasaka Y, Kawasaki M, Sakane T, Omatsu H, Moriya Y, Nakamura T, Sakaeda T, Okumura K, Langguth P, Yamashita S. Induction of human P-glycoprotein in Caco-2 cells: Development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab Pharmacokinet 2006; 21: 414-423.
25. Webb M, Raphael CL, Asbahr H, Erber WN, Meyer BF. The detection of rhodamine 123 efflux at low levels of drug resistance. Br J Haematol 1996; 93: 650-655.
26. Henmi K, Yoshida M, Yoshikawa N, Hirano T. P-glycoprotein functions in peripheral-blood CD4+ cells of patients with systemic lupus erythematosus. Biol Pharm Bull 2008; 31: 873-878.
27. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293-298.
28. Meaden ER, Hoggard PG, Khoo SH, Back DJ. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002; 262: 159-165.
29. Perloff MD, von Moltke LL, Fahey JM, Greenblatt DJ. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 2007; 59: 947-953.
30. Mechetner E. Detection of the MDR1 P-glycoprotein expression and function. Methods Mol Biol 2007; 378: 175-193.
31. Daoud R, Kast C, Gros P, Georges E. Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). Biochemistry 2000; 39: 15344-15352.
32. De Moerloose B, Dhooge C, Philippe J. Discordance of P-glycoprotein expression and function in acute leukemia. Adv Exp Med Biol 1999; 457: 107-118.
33. Fazlina N, Maha A, Zarina AL, Hamidah A, Zulkifli SZ, Cheong SK, Ainoon O, Jamal R, Hamidah NH. Assessment of P-gp and MRP1 activities using MultiDrugQuant assay kit: A preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients. Malays J Pathol 2008; 30: 87-93.